Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of Gene Polymorphism on the Pharmacokinetics and Clinical Outcomes of Rivaroxaban: State-of-the-Art Review

1 Aug 2025

Abstract excerpt

Abstract: Rivaroxaban is a direct oral anticoagulant (DOAC) that directly inhibits coagulation factor Xa and exerts its anticoagulant effects. Although rivaroxaban generally exhibits predictable pharmacokinetic (PK) and pharmacodynamic (PD) profiles, significant interindividual variability in therapeutic responses exists. Research on the role of genetic factors in the clinical variability of rivaroxaban is...

Topics

Join the communities discussing this publication.

Antiplatelet Therapy and Cardiovascular Diseases
Atrial Fibrillation Management and Outcomes
Pharmacogenetics and Drug Metabolism

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40896201
DOI: 10.2147/dddt.s534569

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of Gene Polymorphism on the Pharmacokinetics and Clinical Outcomes of Rivaroxaban: State-of-the-Art ReviewPMID 40896201Read ↗

Pharmacogenetics of Novel Oral Anticoagulants: A Review of Identified Gene Variants & Future PerspectivesSemantic proximity Read ↗

The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillationSemantic proximity Read ↗

PHARMACOGENOMICS OF NOVEL ORAL ANTICOAGULANTS (NOACs): CURRENT INSIGHTS AND FUTURE DIRECTIONSSemantic proximity Read ↗

Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic VariantsSemantic proximity Read ↗

Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants.Semantic proximity Read ↗

Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort studySemantic proximity Read ↗

The Pharmacogenetic Variability Associated with the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Healthy Chinese Subjects: A National Multicenter Exploratory Study.Semantic proximity Read ↗

Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic eventsSemantic proximity Read ↗

Association of Genetic Variants With Rivaroxaban Pharmacokinetics and Pharmacodynamics and Hemorrhage Risk Factors in Patients With Venous Thromboembolism.Semantic proximity Read ↗

Pharmacogenetics of Antiplatelets and Anticoagulants: A Report on Clopidogrel, Warfarin and DabigatranSemantic proximity Read ↗

Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case SeriesSemantic proximity Read ↗

Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.